Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: Chem Biol Drug Des. 2014 May 13;84(2):140–147. doi: 10.1111/cbdd.12303

Figure 3.

Figure 3

(A) ESI-MS of eGFP-CVIA (12). (B) Deconvoluted mass spectrum of eGFP-CVIA. (C) Deconvoluted mass spectra of eGFP-CVIA that was subjected to enzymatic modification using trans-cyclooctene geranyl diphosphate (2) and PFTase. (D) Deconvoluted mass spectra of trans-cyclooctene labeled eGFP-CVIA that underwent tetrazine ligation with benzylamino-tetrazine (4).